Riskpilot← Back to searchSign inGet full accessGefle Läkargrupp AB
ABActiveOrg 5592288855Gefle Läkargrupp Hälsocentral Kaplansgatan 10General medical practice activities · NACE 8621Est. 20190 employees
Revenue 2025
SEK 27,9M
-15% vs 2024
EBITDA margin
11.7%
+2% vs 2024
Equity ratio
62.2%
Financial strength
Net profit 2025
SEK 2,5M
-35% vs 2024
| Revenue | SEK 27,9M | -15% |
| EBITDA | SEK 3,3M | +2% |
| Net profit | SEK 2,5M | -35% |
| Total assets | SEK 8,5M | -33% |
| Equity | SEK 5,3M | -13% |
| Employees | 0 | — |
Legal name
Gefle Läkargrupp AB
Org number
5592288855
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
28 november 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva hälsocentral och därmed förenlig verksamhet.
Address
Gefle Läkargrupp Hälsocentral Kaplansgatan 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 656 | 24 549 | 30 348 | 32 722 | 27 857 |
| Staff expenses | — | — | −16 067 | −20 935 | −16 934 |
| EBITDA | 552 | 8 641 | 7 570 | 3 188 | 3 255 |
| Depreciation & amort. | −202 | −245 | −282 | −223 | — |
| EBIT | 350 | 8 396 | 7 288 | 2 965 | 3 255 |
| Net financials | — | −8 | −6 | −31 | −65 |
| Profit before tax | 349 | 6 254 | 5 564 | 4 938 | 3 238 |
| Tax | −79 | −1 290 | −1 161 | −1 050 | −694 |
| Net profit | 270 | 4 964 | 4 402 | 3 888 | 2 544 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 036 | 10 449 | 15 656 | 12 715 | 8 482 |
| Equity | 320 | 5 285 | 6 687 | 6 075 | 5 279 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 3 716 | 3 030 | 5 116 | 4 791 | 1 403 |
| Total debt | 3 716 | 3 030 | 5 116 | 4 791 | 1 403 |
EBITDA margin
11.7%
This company
15.8%
Market median
-26% vs market
20212025
Equity ratio
62.2%
This company
38.2%
Market median
+63% vs market
20212025
Return on equity
48.2%
This company
18.4%
Market median
+162% vs market
20212025
Net profit margin
9.1%
This company
8.1%
Market median
+12% vs market
20212025
Asset turnover
3.28×
This company
1.12×
Market median
+193% vs market
20212025
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2019-11-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Audit | 2020 | |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2024 | |
| Chairman | 2024 | |
| Former (3) | ||
| Chairman | 2020 – 2024 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gefle Läkargrupp AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Linda Maria Löfgren Andersson | Audit | 0 companies |
| Karwan Khder Sinjawi | Board of Directors | 0 companies |
| Riadh Abed Nasser | Chairman | 0 companies |
| Dawan Semarp | Deputy Board Member | 0 companies |
| Zafer Mourad | Board of Directors | 0 companies |
| Bestoun Faruq Namiq | Board of Directors | 0 companies |
| Zirak Omer Sherlan | Chairman | 0 companies |